EDITORIAL COMMENT

RICORS2040: the need for collaborative research in chronic kidney disease

Alberto Ortiz

on behalf of Asociación Información Enfermedades Renales Genéticas (AIRG-E), European Kidney Patients’ Federation (EKPF), Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón (ALCER), Fundación Renal Íñigo Álvarez de Toledo (FRIAT), Red de Investigación Renal (REDINREN), Resultados en Salud 2040 (RICORS2040), Sociedad Española de Nefrología (SENEFRO) Council, Sociedad Española de Trasplante (SET) Council, Organización Nacional de Trasplantes (ONT)

Correspondence to: Alberto Ortiz; E-mail: aortiz@fjd.es

ABSTRACT

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is ‘solved’ by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020–2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón.
CHRONIC KIDNEY DISEASE: AN EVOLVING CONCEPT IN NEED OF UPDATING

The Kidney Disease: Improving Global Outcomes consensus defines chronic kidney disease (CKD) as abnormalities of kidney structure or function present for >3 months with implications for health [1]. Just one criterion identifying abnormal kidney structure or function allows the diagnosis of CKD. Criteria include a low glomerular filtration rate (GFR; <60 mL/min/1.73 m²) or evidence of kidney damage such as pathological albuminuria (urinary albumin:creatinine ratio [UACR] ≥30 mg/g); abnormal urine sediment, histology or imaging; abnormalities due to tubular disorders or kidney transplantation. In clinical practice, this means that diagnosing CKD when GFR is ≥60 mL/min/1.73 m² requires urinalysis or kidney imaging. A recent conceptual manuscript summarized the key features of CKD for non-nephrologists, as there is ongoing confusion, even in high-quality journals, such as the New England Journal of Medicine [2].

A CKD diagnosis implies an increased risk of progressing to require kidney replacement therapy (KRT), of all-cause and cardiovascular death and of acute kidney injury (AKI) [1, 3–5]. There is a bidirectional relationship between CKD and AKI. CKD is the main risk factor for AKI and AKI may accelerate CKD [6]. AKI has a high mortality and increases the risk of death for >1 year after the episode [6]. AKI is also common, as ~5% of hospitalized patients develop in-hospital AKI [7]. More recently, CKD has been identified as the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and as the factor that most increased the risk of death in COVID-19 after older age [8–10] (Figure 1). AKI is also common in COVID-19 and a key risk factor for death [8].

Correct CKD diagnoses require indicating cause and G (GFR: G1–G5) and A (albuminuria: A1–A3) categories. Increasing CKD categories are associated with an increased risk of all-cause and cardiovascular death, even in the elderly (Figure 2A and B). The G1 (GFR >90 mL/min/1.73 m²) and A1 (UACR <30 mg/g) categories are not diagnostic of CKD by themselves. Persons in category G1A1 must fulfill an additional criterion to be diagnosed with CKD, such as imaging diagnostics of polycystic kidney disease (PKD) [1, 2]. The autosomal dominant PKD paradigm illustrates the way to go: a diagnostic test (sonography) allows the diagnosis of CKD decades before patients fulfill any other criterion to diagnose CKD, including the most commonly used ones such as GFR and UACR thresholds [11]. Similar diagnostic tools are needed for other forms of CKD, as by the time GFR falls to 60 mL/min/1.73 m², CKD has progressed unnoticed (potentially over years and even decades) to destroy >50% of the functioning kidney mass. Similarly, albuminuria as low as ≥2.5 mg/g is already associated with an increased risk of premature death (Figure 2B). Again, the current albuminuria threshold used to diagnose CKD is a late event. There is a clear margin for earlier diagnosis and therapy of CKD. Additional future criteria to diagnose CKD may be envisioned, such as genetic tests disclosing clearly pathogenic gene variants or urinary biomarkers beyond UACR, including urinary peptidomics [12, 13].

Kidney failure (end-stage kidney disease, G5, GFR <15 mL/min/1.73 m²) is probably the only form of kidney disease well known to the wider public, non-nephrologists and healthcare authorities. Non-experts usually equate the burden of CKD with the burden of KRT for kidney failure. Despite care for KRT patients representing a disproportionate percentage of the healthcare budget (the roughly 64,292 persons on KRT in Spain consume 2.5–5.0% of the healthcare budget), the bulk of the health burden of CKD is not represented by KRT but by accelerated ageing and premature death, as clearly quantified by Global Burden of Disease (GBD) data discussed below [14]. However, there are no registries in Spain for persons with CKD not on KRT as is the case for many other countries.

KRT: A SUCCESS STORY OR A STORY OF FAILURE?

KRT has been hailed as one of the success stories of healthcare that allows survival when a vital organ has failed. Counterintuitively, this reflects only a partial view of the facts. Rather, KRT should be considered a failure of CKD management, as the expected remaining lifetime is severely reduced—by ~70% (40 years less) and by 25% (15 years less) for a 20-year-old on dialysis or with a functioning kidney graft, respectively [15, 16]. The absolute reduction in the expected remaining lifetime is less at older ages, but the relative reduction in life expectancy remains constant up to age 89 years (Figure 3A). The fact that the mortality of kidney failure remains high, up to 100-fold higher in patients on KRT than for similar-aged controls [5], is not well known by health authorities and may hinder funding for CKD research. Indeed, the 5-year survival of patients on dialysis is lower than for all forms of cancer combined [17] (Figure 3B).

THE MOST COMMON CAUSE OF CKD IS UNKNOWN: THE NEED TO REDEFINE THE CKD AETIOLOGY LANDSCAPE

The most common cause of KRT in Spain is diabetes (25% of persons initiating KRT), followed by unknown (15%), ‘vascular’, glomerulonephritis (14%) and inherited kidney disease [15, 16, 18]. The magnitude of the inherited category is difficult to assess as it is usually divided into PKD and others. Others are usually lumped into a ‘miscellaneous’ category or misdiagnosed as glomerular or interstitial CKD. Recent analysis of the Madrid and Catalan KRT registries has disclosed that inherited kidney disease is as frequent as glomerulonephritis [19]. Inherited kidney diseases are frequently overlooked by physicians as illustrated by whole-exome sequencing findings of monogenic kidney diseases in 9% of adults on KRT [15, 16, 18].

‘Vascular’ mainly means hypertension, and it is labelled as hypertension in the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Registry [15, 16, 18]. In clinical practice, hypertension is usually listed as a cause when there is no other obvious aetiology, following expert recommendation [22]. This practice has been criticized, as it may replace an inadequate aetiologic workup, likely downplaying the incidence of other causes of CKD while falsely boosting...
hypertension as a cause (rather than as consequence) of CKD [23, 24]. Thus there is no relationship between the prevalence of hypertension and hypertensive CKD in different countries [23]. In African Americans, hypertensive nephropathy has long been shown to represent a familial predisposition to CKD triggered by different causes, i.e. it would be better classified as inherited kidney disease accelerated by triggers such as human immunodeficiency virus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [25].

The ERA-EDTA Registry provides more elaborate data (Spanish data are made public on websites but not regularly published in journals by themselves) and a European-wide perspective [15, 16]. In ERA-EDTA Registry data for all countries, the most common cause of incident KRT was unknown (27%, increasing to 39% if we add hypertension) followed by diabetes (20%), glomerulonephritis (11%) and PKD (5%). For prevalent KRT, the ranking is unknown (27%, increasing to 35% by adding hypertension) followed by glomerulonephritis (19%), diabetes (15%) and PKD (8%). This identifies a major issue in CKD. A significant percentage of persons lack an aetiological diagnosis, which precludes aetiology-targeted therapy and early prevention campaigns. Among the fastest-growing segment of CKD patients (those >65 years of age), unknown and hypertension accounted for 43% of incident KRT patients, highlighting the need to define cause in the elderly. We propose that accelerated kidney ageing may be a key contributor to CKD, including in the elderly, and are currently devising a working definition for accelerated kidney ageing that spurs research in this field.

THE GROWING BURDEN OF CKD

Globally, ~850 million persons have CKD [26]. The GBD study has generated data on the global and local burden of CKD, while

![Figure 1](https://academic.oup.com/ckj/advance-article/doi/10.1093/ckj/sfab170/6374449)

**FIGURE 1:** CKD is the most prevalent risk factor for severe COVID-19 and also the risk factor for severe COVID-19 that is associated with the highest risk of death, after old age. (A) CKD as a percentage of persons at risk of severe COVID-19 on a global scale. Data from Clark et al. [10]. (B) Risk of death associated with pre-existent conditions in patients with COVID-19 in an adjusted analysis. Data from Williamson et al. [9]. Reproduced from ERA-EDTA Council and ERACODA Working Group [8].

![Figure 2](https://academic.oup.com/ckj/advance-article/doi/10.1093/ckj/sfab170/6374449)

**FIGURE 2:** CKD is associated with an increased risk of death even in the very elderly. All-cause mortality rate (absolute risk) for different (A) eGFR and (B) UACR values by age categories based on weighted average across cohorts, adjusted for covariates. A steeper slope at an older age indicates a higher absolute risk difference associated with low eGFR as compared with younger age categories: the discontinuous green line represents the overlay of the risk for the very elderly on top of the risk line for the younger age range. Similar trends were observed for albuminuria. Conceptual representation of data presented in Hallan et al. [4]. In panel A, an increase in the risk of death observed in patients >55 years of age with higher eGFR values is not shown, as this is thought to be an artefact depending on lower muscle mass of patients who were sicker at baseline.
Spanish epidemiological studies provide information on the local prevalence of CKD and the epidemiology of KRT.

In 2017, 1.2 million people died from CKD globally and CKD resulted in 35.8 million disability-adjusted life years (DALYs), most of them (>70%) not due to diabetic kidney disease (DKD), as well as in 7.3 million years lived with disability (YLD) and 28.5 million years of life lost (YLL) [27]. Considerable global variation was noted in CKD burden. Age-standardized CKD DALY rates varied >15-fold between countries, a variability also evident within Spain and even within Spain autonomous communities [15, 27]. This illustrates the need for interregional collaborative research to identify and correct the drivers of a higher burden in certain regions.

The GBD projected that CKD will become the fifth greatest global cause of death by 2040 [14] (Figure 4B). YLL due to CKD are expected to double by 2040, the fastest increase among major causes of death after Alzheimer’s. In contrast, the burden of other major causes of death is projected to decrease (e.g. ischemic heart disease ~3.6% or stroke ~10.7%). Interestingly, CKD growth as a global cause of death outpaces diabetes, illustrating the need to address non-diabetic causes of CKD and protect the kidneys in persons with diabetes. Spain GBD data identified CKD as the eighth greatest cause of death, representing the largest departure from official Instituto Nacional de Estadística (INE) data among causes of death in Spain. The INE underestimated the burden of CKD, likely due to low awareness of the condition [28, 29]. Spain’s GBD identified CKD as the second fastest-growing cause of death, the sixth fastest-growing cause of YLD and the seventh fastest-growing cause of DALYs among the top 25 causes for each category [28, 29]. Projecting into the future, the recent rate of increase of CKD in Spain’s GBD, CKD will become the second leading cause of death, after Alzheimer’s, before the end of the century [29] (Figure 5A). This is likely an underestimation, as the progressive change in the age pyramid over the next few decades was not considered. Spanish projections may also apply to other countries with long life expectancies.

The population of Spain is projected to peak in the present decade and to become progressively older and decrease to ~23–33 million by 2100 [30, 31]. The most recent estimate of the number of persons with CKD dates from 2010, when 14% of Spanish adults (6.7 million) had CKD [32]. CKD was more common in men than in women and a majority of persons with CKD were in the 45- to 64-year age range. Projecting these numbers into the future in the absence of changes to the current standard of care, assuming a constant prevalence of CKD within each age range and gender group and using World Health Organization (WHO) population prediction estimates, results in at least 8.12 million persons with CKD by 2040 and 7.96 million by 2100, which will represent 18% and 24% of the Spanish population, respectively (Figure 5B and C). This is an underestimation, as progressive ageing of the population (persons ≥65 years of age are estimated to increase from 17% in 2010 to 32% by 2040 and 35% by 2100) will also occur within the same age range category, and this would be associated with an increased prevalence of CKD within age categories. Additionally, by 2040, most persons with CKD will be ≥65 years old.

The prevalence of KRT in Spain is also increasing. It increased 38% from 2007 to 2019 [985 to 1367 per million population (pmp)] and the rate appears to be accelerating (it increased 14% from 2007 to 2013 and 22% from 2013 to 2019). At this rate of growth, the number of persons on KRT will hit 0.23–1.00
million by the end of the century, i.e. ~1–4% of the projected population of Spain at that time (Figure 5D). The incidence of KRT also increased by 22% from 2013 to 2019 (125–152 pmp) [18] (Figure 5E). A majority of persons on KRT in Spain (55%) have a functioning kidney graft. Thus improving kidney and person outcomes in kidney graft recipients is a major aim in kidney research. As for CKD, KRT is also more common in men than in women. Therefore studies on CKD or KRT that do not split by gender may reflect the disease in men and studies addressing risk stratification, diagnosis and therapeutic approaches independently...
for men and women are required. Furthermore, there are large regional differences (range of incident KRT is 85–197 pmp and of prevalent KRT is 740–1567 pmp for different Spanish regions), which are also observed within regions (e.g. in Madrid, the range of incident KRT is 50–200 pmp and of prevalent KRT is 980–1700 pmp for different healthcare catchment areas). The causes of these differences are not fully understood, but it is critically important to define them in order to identify and target factors that generate CKD hotspots or benchmark potential healthcare contributors [33].

The burden of CKD is also economic. The extrapolated annual cost of all CKD is at least as high as that for cancer or diabetes and estimated at $140 billion annually in Europe and $130 billion in the USA [17, 34] (Figure 6).

THE RATIONALE FOR RICORS2040

From 2022, the Instituto de Salud Carlos III (ISCIII, a Spanish government agency that funds health research) will fund the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS; Cooperative Research Networks Focused on Results in Health) programme of network research. This will replace the prior ISCIII-funded programme of network research called RETICS (Network for Cooperative Research in Health). The Spanish kidney research community, represented by the research groups integrated into the Kidney Research Network RETIC (RETIC REDINREN) and by several working groups of the Spanish Society of Nephrology [Sociedad Española de Nefrología (SEN)], such as GLOSEN (glomerular disease working group) and GEENDIAB (diabetes working group), has submitted the RICORS2040 proposal to the RICORS call. RICORS2040 is supported by the Sociedad Española de Nefrología (SENEFRO), the ERA-EDTA, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón (Spanish Kidney Patients Association) and Organización Nacional de Trasplantes (ONT). RICORS2040 is focused on kidney diseases within one of the four thematic areas of the RICORS call: ‘inflammation and immunopathology of organs and systems’ [35]. This thematic area includes kidney diseases and also other topics,
CKD as a chronic inflammatory disease

CKD can be characterized as a local inflammatory disease that becomes a systemic inflammatory disease as it progresses. Indeed, activation of the master regulator of inflammation [nuclear factor (NF)-κB], local expression of inflammatory cytokines and immune cell infiltrates are already observed in the early stages of CKD and can be triggered by albuminuria, hyperglycaemia and genetic defects, among others [36, 37] (Figure 7A). Kidneys have multiple functions and GFR, which is usually estimated (not measured) in routine clinical care, is just one of them. There is increasing evidence that production of the anti-inflammatory and anti-inflammatory factor Klotho is a key function of kidney tubules that is lost very early in the course of CKD (GFR category G1, i.e. normal kidney function) partly in response to local inflammation and/or albuminuria [38–40] (Figure 7B). Loss of anti-inflammatory molecules and accumulation of uraemic toxins leads to systemic inflammation, which is a key predictor of cardiovascular events and death in CKD, likely contributing to the accelerated biological ageing that characterizes CKD [41, 42]. The immune response also causes native kidney injury and is a leading cause of chronic graft injury.

Current versus future burden: the decade of the kidney

We strongly believe that current research should be guided by future projections of disease burden rather than by past statistics. Predictions for the global impact of CKD are dire. RICORS2040 derives its name from its aim to prove wrong the projections that CKD will become the fifth leading global cause of death by 2040. In this regard, RICORS2040 is fully aligned with the Decade of the Kidney concept first established by the American Association of Kidney Patients for 2020–2030, given the realization that CKD care lags other major causes of death in terms of current outcomes, predicted outcomes in the next decades and research funding [43]. This was followed by the Advancing American Kidney Health (AAKH) initiative of the USA government that is expected to become a catalyst for investment in kidney disease clinical trials and precision medicine [44]. The Decade of the Kidney is supported by the European Kidney Health Alliance (EKHA) and by patient associations across Europe that have launched a European movement for 2021–2030 [17, 43]. The RICORS2040 leadership is actively contributing to EKHA efforts.

Emphasis on prevention

RICORS2040 is focused on preservation of native and graft kidney function and improving outcomes in persons with CKD by preventing systemic consequences of CKD, collectively grouped into the concept of accelerated biological ageing, including consequences of kidney transplantation and its therapy (Figure 8), as a majority of persons on KRT in Spain have a kidney graft. Thus, preventing the need for KRT in men and women with native kidneys or kidney grafts and improving kidney and patient outcomes in kidney graft recipients are major aims of RICORS2040. Risk stratification and optimization of therapeutic approaches to improve quality of life and life expectancy in the dialysis population are also addressed.

Men and women

There is mounting evidence that course and complications of CKD are not the same in men and women and even the cut-off points to define CKD may differ [45]. However, we still use the same metric and the same cut-off points to diagnose CKD and for risk stratification in men and women, even knowing that creatinine excretion differs and therefore the denominator for UACR differs for men and for women. RICORS2040 will address the factors behind the gender gap in CKD burden and aims to provide clinical guidance for both men and women and to identify information gaps that preclude a gender-conscious approach to the diagnosis, risk stratification and treatment of CKD.

Addressing regional inequality

RICORS2040 will also address the factors behind geographical differences in CKD burden as it incorporates multiple centres from all over Spain. Specifically, kidney research and care centres from 12 of the 17 Spanish regions (autonomous communities) encompassing 90% of the Spanish population are integrated into RICORS2040.

Clinical guidance should be implemented

A key issue hampering the achievement of health outcome targets is the poor implementation of clinical guidance documents. In this regard, clinical guidance documents are rarely validated in real-world clinical practice to assess potential shortcomings or barriers to implementation. RICORS2040 will use continuous improvement approaches to generate, validate and improve clinical guidance documents for different causes of CKD as well as for assessing and slowing the progression of CKD and the
associated accelerated biological ageing of organs and systems in men and women with native kidneys or with kidney grafts. Testing the implementation of clinical guidance documents in a large number of centres from different regional health systems under real-world conditions will allow identification and correction of most shortcomings and feasibility issues.

In summary, RICORS2040 is focused on decreasing the need for KRT by improving prevention, diagnosis and therapy for major causes of CKD (diabetic, glomerular, inherited and accelerated kidney ageing; the latter is a concept that RICORS2040 is developing) in native kidneys and of chronic allograft nephropathy as well as on improving outcomes of men and women with CKD by preventing, identifying and treating major consequences of CKD or its therapy that contribute to the burden of accelerated ageing and premature death (Table 1). This will be achieved through systematization of prior knowledge generated by its antecedent REDINREN and the international community into gender-conscious clinical guidance documents, novel research to address gaps of knowledge and monitoring of clinical guidance implementation to generate updated clinical guidance documents as output of RICORS2040.

FIGURE 7: CKD as a local and systemic inflammatory disease leading to accelerated biological ageing. (A) Albuminuria itself may trigger kidney inflammation as illustrated by the albumin overload model in mice: pathological albuminuria triggered interstitial macrophage (F4/80-positive cells) infiltration (data shown) while kidney function was preserved (data not shown) [37]. Thus albuminuria induces the loss of a key kidney function (production of the anti-inflammatory, anti-fibrosis and anti-ageing protein Klotho) well before the kidney function assessed in routine clinical care (eGFR) is lost. (B) Decreased urinary Klotho in persons with CKD G1/G2 (i.e. higher eGFR levels that per se are not diagnostic of CKD) with pathological albuminuria (consistent with cell culture and in vivo preclinical models in which inflammatory cytokines or albumin/albuminuria decreased tubular cell Klotho production by healthy tubular cells) and also in persons with CKD G3–5 (i.e. reduced eGFR, diagnostic, by itself, of CKD). In CKD G3–5 the decrease in Klotho is likely the consequence, in part, of decreased tubular cell mass. (C) Decreased urinary Klotho in persons with pathological albuminuria and preserved eGFR and also in persons with decreased eGFR irrespective of albuminuria. Vertical axis reflects urinary Klotho, horizontal axis reflects eGFR and diameter of circles reflects the magnitude of albuminuria [37].

FIGURE 8: RICORS2040 concept and overall structure and research aims. RICORS2040 aims at improving kidney and person outcomes in both men and women with CKD. There are two sets of aims. The first set aims at improving the diagnosis and management of the most common causes of CKD to prevent or delay CKD progression. For this, the main causes of native kidney CKD (diabetes, glomerular, inherited/genetic) will be addressed and the accelerated kidney ageing concept will be explored as a final common pathway of CKD progression and as a potential cause of CKD in persons in whom no other cause is identified. Since the life expectancy of kidney allografts is markedly shorter than for native kidneys, chronic allograft dysfunction will also be explored. The second set aims to improve person outcomes by optimizing the diagnosis and management of the consequences of CKD (or of kidney transplantation therapy) on other organs and systems, what we have collectively called the accelerated biological ageing of CKD. Please note that Aim 4 is focused on accelerated kidney ageing as a cause of CKD and on kidney events, while Aim 6 is focused on the impact of CKD on other organs and systems, i.e. on accelerated biological ageing of diverse organs and systems occurring as a consequence of CKD. Care will be taken to identify and optimize the management of gender-related issues and provide clinical guidance with specific information for men and for women.
The general aim of RICORS2040 is to improve kidney and person outcomes in men and women with CKD or at high risk of CKD. The name derives from the aim to prove wrong the dire predictions regarding the global burden of CKD by 2040, which closely reflects those for Spain: the GBD collaboration predicts that CKD will become the fifth leading global cause of death by 2040.

Specific aims:
1. Improve kidney outcomes in men and women with diabetes or DKD
   Improve risk stratification in DKD to foster precision nephrology
   Evaluate novel strategies for kidney protection through therapeutic drug repositioning
   Develop, evaluate and update the Spanish Clinical Practice Guideline for detection and management of DKD
2. Improve kidney outcomes in men and women with primary glomerular disease
   Improve risk stratification in glomerular disease to foster precision nephrology
   Evaluate novel kidney protective approaches in primary glomerular disease
   Develop, evaluate and update clinical guidance documents
3. Improve kidney outcomes in men and women with inherited kidney disease
   Increase awareness of inherited kidney disease with special focus on glomerular and tubular kidney disease
   Improve risk stratification in inherited glomerular disease to foster precision nephrology
   Identify genetic predictors of CKD progression
   Develop, evaluate and update clinical guidance documents
4. Define accelerated kidney ageing as a cause of CKD and slow the loss of GFR in men and women
   Develop a working definition of accelerated kidney ageing
   Develop tools to predict and assess rapid CKD progression
   Test novel therapeutic approaches to kidney protection
   Develop, evaluate and update clinical guidance documents
5. Improve kidney allograft outcomes and improve the outcomes in men and women with a functioning kidney graft
   Improve the outcome of chronic allograft nephropathy, decreasing graft loss
   Limit the negative impact of immunosuppressive therapies on comorbidities and life-threatening complications
   Develop, evaluate and update clinical guidance documents for precision immunosuppression
6. Improve the outcomes of men and women with CKD by targeting the accelerated biological ageing that is a consequence of CKD
   Develop novel risk stratification tools for cardiovascular disease and CKD-mineral and bone disorder (MBD) to foster precision nephrology
   Improve the recognition and outcome of frailty
   Evaluate the long-term safety and efficacy of SARS-CoV-2 vaccines in persons with advanced CKD
   Develop, evaluate and update clinical guidance documents on key consequences of CKD, such as cardiovascular disease, CKD-MBD, frailty and susceptibility to severe SARS-CoV-2 infection

MAJOR SHORTCOMINGS IN SPAIN’S HEALTH RESEARCH FUNDING STRUCTURE

The ISCIII is the main funder of health research in Spain and has long fostered successful collaborative research structures through dedicated research centres [e.g. Spanish National Cancer Research Centre (CNIO) and Spanish National Cardiovascular Research Centre (CNIC)]. Additionally, the ISCIII currently funds research networks for most major predicted 2040 global causes of death [14]: ischaemic heart disease (CIBERCV), stroke (CIBERCV and from 2022, stroke RICORS), infection (CIBER from 2022) and chronic obstructive pulmonary disease. The ISCIII research networks also fund projected 2040 causes of death ranked below CKD (e.g. CIBERONC for cancer and CIBERDEM for diabetes). In fact, in 2022, CKD will become the only top-15 predicted worldwide cause of death that is not supported by the ISCIII CIBER programme (Figure 4B). This represents a major, correctable gap in Spain’s health research funding structure since there is also no dedicated research centre for kidney research. In this environment, the success of RICORS2040 would be critical for the survival of collaborative kidney research in Spain, although the ultimate aim would not be survival, but expansion according to the projected global burden of CKD.

SUPPLEMENTARY DATA

Supplementary data are available at ckj online.

FUNDING

This study was supported by REDINREN RD16/0009 by the Instituto de Salud Carlos III (ISCIII).

CONFLICT OF INTEREST STATEMENT

Authors are members of scientific and patient associations with an interest in improving the outcomes and quality of life of persons with kidney disease. A.O. is Editor in Chief for Clinical Kidney Journal, Maria Jose Soler is Associate Editor and Editor in Chief elect for Clinical Kidney Journal and Roser Torra and Jose Maria Cruzado are Associate Editors for Clinical Kidney Journal.

APPENDIX

Asociación para la información y la investigación de las enfermedades renales genéticas (AIRG-E)
Marta Roger
Presidenta
Víctor Martínez Jiménez
Hospital Virgen de la Arrixaca de Murcia
José Carlos Rodríguez Perez Hospital Universitario de Gran Canaria Dr. Negrín
Mónica Furlano Fundació Puigvert
Laia Sans AtxerParc De Salut Mar
Federación Europea de Pacientes Renales (EKPF)
Daniel Gallego Zurro
Asociación para la lucha Contra las Enfermedades Renales (ALCER):
Carlos María Romea Casabona
Daniel Gallego Zurro
Clemente Gómez Gómez
Pilar Pérez Bermúdez
Manuel Arellano Armisen
Santiago Ábaladejo López
Inmaculada Gutiérrez Forras
Josefa Gómez Ruiz
José Manuel Martín Orgaz
Marta Moreno Barón
Sociedad Española de Nefrología (SENFRON) council:
Patricia de Sequera Ortiz Hospital Universitario Infanta Leonor
Gabriel de Arribas de la Fuente Hospital Universitario de Guadalajara
Borja Quirogo Gil Hospital Universitario de la Princesa
Gema Fernández Fresnedo Hospital Universitario Marqués de Valdecilla
Sagrario Soriano Cabrera Hospital Universitario Reina Sofía de Córdoba
Javier Pérez Contreras Hospital General Universitario de Alicante
Miquel Blasco Pelicano Hospital Clinic de Barcelona
Auxiliadora Mazuecos Blanca Hospital Puerta del Mar
Mariano Rodríguez Portillo Hospital Universitario Reina Sofía de Córdoba
J. Emilio Sánchez Álvarez Hospital Universitario de Cabueros
María José Soler Romeo Hospital Universitario General Vall d’Hebrón
Manuel Gorostidi Pérez Hospital Universitario Central de Asturias
Marian Goicoechea Diezhandino Hospital General Universitario Gregorio Marañón
Sociedad Española de Trasplante (SET) council,
Domingo Hernández Marrero Trasplante Renal. Hospital Regional Universitario de Málaga
Constantino Fondevila Campo Trasplante Hepático. Hospital Clinic de Barcelona
Eduardo Mínambres García Coordinación Trasplantes. Hospital Universitario Marqués de Valdecilla
Dolores García Cosío Carmona Trasplante Cardiaco. Hospital 12 de Octubre
Armando Torres Ramírez Trasplante Renal. Hospital Universitario de Canarias
Luis Muñoz Bellvis Cirugía B.P. Complejo Asistencial Universitario de Salamanca
Marina Berenguer Haym Trasplante Hepático. Hospital Universitario y Politécnico de la Fe
Manuel Barrera Gómez Trasplante Hepático. Hospital Universitario Nuestra Señora de la Candelaria
José Manuel Cifrián Martínez Grupo de Trasplante Pulmonar.
Hospital Universitario Marqués de Valdecilla
Josep María Garrido Garrido Trasplante Renal. Hospital Universitario de Bellvitge
Rafael San Juan Garrido Especialidad en Enfermedades Infecciosas. Hospital 12 de Octubre
Javier Briceno Delgado Asociación Española de Cirugía. Hospital Universitario Reina Sofía de Córdoba
Marta Bodro Marimont Grupo de Estudio en el Trasplante (GESITRA)/Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Hospital Clinic de Barcelona
María O. Valentín Muñoz Organización Nacional de Trasplantes (ONT)
José Miguel Pérez Villares Sociedad Española de Medicina Intensiva Crítica y Unidades Coronarias (SEMICYUC). Hospital Universitario Virgen de las Nieves
Ángel Salvatierra Velázquez Grupo de Trasplante de Pulmón de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Hospital Universitario Reina Sofía de Córdoba
Luis Almenar Bonet Sección Trasplante Cardiaco de la Sociedad Española de Cardiología. Hospital Universitario y Politécnico de la Fe de Valencia
Miguel Ángel Gómez Bravo Sociedad Andaluza de Trasplantes. Hospital Virgen del Rocío
Francisc J. Moreso Mateos Sociedad Catalana de trasplantes. Hospital Universitario Vall d’Hebrón
Manuel Muro Amador Sociedad Española de Inmunología. Murcia. Hospital Virgen de la Arrixaca
Auxiliadora Mazuecos Blanca Sociedad Española de Nefrología. Hospital del Mar
José A. Pons Mirano Sociedad Española de Trasplante Hepático. Hospital Virgen de la Arrixaca
Amado Andrés Belmonte Sociedad Madrileña de Trasplantes. Hospital 12 de Octubre
Amparo Solé Jover Sociedad Valenciana de Trasplante. Hospital Universitario y Politécnico de la Fe
Daniel Casanova Ruiz European Union of Medical Specialists (UEMS) Committee Board. Hospital Universitario Marqués de Valdecilla
Fernando Pardo Sánchez UEMS Committee Board. Clínica Universidad de Navarra.
Fundación Renal Íñigo Álvarez de Toledo:
María Dolores Arenas MD PhD
Roberto Martín Hernández MD
Blanca Miranda Serrano MD PhD
RICORS2040/REDINREN:
Alberto Ortiz Arduan Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Ana B Sanz Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Adrián M Ramos Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Gina Córdoba-David Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Jorge García-Jiménez Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Miguel Fontecha-Barruso Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Juan Guerrero-Mauvecin Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Ana M. Lopez-Díaz Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
María Dolores Sánchez-Niño Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Lara Valino-Rivas Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Leticia Cuarental Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz
The need for collaborative research in CKD | 11
María Encarnación Rodríguez OrtizInstituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)
Julio Manuel Martínez MorenoInstituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)
Ana Isabel Raya BermejuzInstituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)
Rafael Santamaría Olmo Hospital Reina Sofia
Fátima Guerrero Pavón Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)

Cayetana Moyano Peregrin Hospital Reina Sofia
Escolástico Aguilera Tejerol Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)
Ignacio Lopez Villabal Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)

Andrés Carmona Munoz Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)
Maria Victoria Pendon Ruiz De Mier Hospital Reina Sofia
Carmen Maria Pineda Martos Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)
Rodrigo Lopez Baltanais Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC)

Cristian Rodelo Haadhospital Reina Sofia
Marcella Franquesa Bartolome Fundación Instituto Germans Trias I Pujol

Francisco Enrique Borras Serres Fundación Instituto Germans Trias I Pujol
Maruja Navarro Diaz Hospital Germans Trias I Pujol
Francisco Javier Juega Marina Hospital Germans Trias I Pujol
Laura Canas Sole Hospital Germans Trias I Pujol
Maria Isabel Troya Saborido Hospital Germans Trias I Pujol
Jordi Soler Majoral Hospital Germans Trias I Pujol
Marina Lopez Martinez Hospital Germans Trias I Pujol

Emilio Rodrigo Calabia Hospital Marqués de Valdecilla/IDIVAL, University of Cantabria
Juan Carlos Ruiz San Millán Hospital Marqués de Valdecilla/IDIVAL, University of Cantabria
Marcos Lopez Hoyos University Hospital Marqués de Valdecilla/IDIVAL, University of Cantabria
Adalberto Benito-Hernández Hospital Marqués de Valdecilla/IDIVAL, University of Cantabria

Gema Fernandez Fresnohospital University Hospital Marqués de Valdecilla/IDIVAL, University of Cantabria
David San Segundo Hospital Marqués de Valdecilla/IDIVAL, University of Cantabria
Rosalia Valero Hospital Marqués de Valdecilla/IDIVAL, University of Cantabria

Eliécer Coto Garcia Hospital Universitario Central de Asturias
Juan Gómez De Ona Hospital Universitario Central de Asturias
Elias Cuesta Llavona Hospital Universitario Central de Asturias

Fernando Santos Rodriguez Hospital Universitario Central de Asturias
Rebeca Lorca Gutiérrez Hospital Universitario Central de Asturias
Helena Gil Pena Hospital Universitario Central de Asturias
Manuel Gorostidi Pérez Hospital Universitario Central de Asturias

Domingo Hernandez Marrero Instituto de Investigación Biomedica de Málaga (IBIMA)
Verónica Lopez Hospital Regional Universitario de Malaga/IBIMA

Mercedes Cabello Hospital Regional Universitario de Malaga/IBIMA
Abeulardo Caballero Hospital Regional Universitario de Malaga/IBIMA
Myriam Leon Hospital Regional Universitario de Malaga/IBIMA
Pedro Ruiz Hospital Regional Universitario de Malaga/IBIMA
Juana Alonso Hospital Regional Universitario de Malaga/IBIMA
Juan Navarro-González Hospital Nuestra Sra. Candelaria, Tenerife
María Del Carmen Mora-Fernández Hospital Universitario Nuestra Señora de Candelaria
Javier Donate-Correa Hospital Universitario Nuestra Señora de Candelaria
Ernesto Martín-Nuñez Hospital Universitario Nuestra Señora de Candelaria
Nayra Pérez Delgado Hospital Universitario Nuestra Señora de Candelaria
Secundino Gigarrán-Guldrls Hospital Da Costa, Burela
José Carlos Rodriguez Pérez Hospital Universitario Dr. Negrín
José Luis Górriz Teruel Hospital Universitario Nuestra Señora de Candelaria
Francisco Javier Juega Hospital Universitario Dr. Negrín
Maria Isabel Troya Hospital Universitario Dr. Negrín

Cristina Martinez Martinez Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)
Josefa Maria Lastra Hospital Clínico Universitario de Valencia
Marina Garcia Cuadrado Hospital Universitario Dr. Negrín
Josefina Reyes Hospital Universitario Dr. Negrín

Josefa Maria Castellano Hospital Universitario Bellvitge, Hospitalet, Barcelona
Jose Manuel Valdivielso Revilla Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)

Milica Bozic Stanojevic Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)
Josefa Maria Castellano Hospital Universitario Bellvitge, Hospitalet, Barcelona
Jose Manuel Valdivielso Revilla Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)

Maria Núria Sans Rosell Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)
Virtudes Maria De Lamol Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)
Juan Miguel Diaz Tocado Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)

Alicia Garcia Carrasco Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)
Marcelino Bermudez Lopez Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)
Maite Causs Enriquez Instituto de Investigación Biomedica de Lleida. Fundación Dr. Pifarré (IRBLLEIDA)

Antonio Osuna Ortega Hospital Universitario Virgen de las Nieves de Granada
Rosemary Wangensteen Fuentes Universidad de Jaén
Maria del Carmen De Gracia Guindo Hospital Universitario Virgen de las Nieves de Granada
María del Carmen Ruiz Fuentes Hospital Universitario Virgen de las Nieves de Granada
Francisco O’Valle Ravassa Universidad de Granada
Mercedes Caba Molina Hospital Universitario San Cecilio
César Luis Ramirez Tortosa Hospital Universitario San Cecilio
Marta Crespo Barrio
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Julio Pascual Santos
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Clara Barrios Barrena
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

María José Pérez Sáez
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

María Dolores Redondo Pachón
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Carlos Arias Cabrales
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Anna Buxeda Porras
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Eva Rodríguez García
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Laia Sans Atxer
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Vanesa Palau González
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Laura Llinas Mallol
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Marta Riera Oliva
Instituto Hospital del Mar de Investigaciones Médicas (FIMIM)

Diego Rodríguez Puyol
Fundación Investigación Biomédica.

Hospital Príncipe de Asturias

María Fiedad Ruiz Torres
Universidad de Alcalá

Susana López Onll
Fundación Investigación Biomédica.

Hospital Príncipe de Asturias

Laura Callejas Basilio
Universidad de Alcalá

Gema Olmos Centenera
Universidad de Alcalá

Patricia Martínez de Miguel
Hospital Universitario Principio de Asturias

Loreto Fernández Rodríguez
Hospital Universitario Principio de Asturias

Hanane Bouarich Nadah
Hospital Universitario Principio de Asturias

María Pérez Fernández
Hospital Universitario Principio de Asturias

Manuel Rafael Ramírez Chamond
Universidad de Alcalá

Patricia Sequera Ortiz
Hospital Universitario Infanta Leonor

Nuria García Fernández
Instituto de Investigación Sanitaria de Navarra (IDISNA),

Alberto Benito Boil
Universidad de Navarra

Nerea Varo Carraubea
Universidad de Navarra

María Asunción Fernández Seara
Universidad de Navarra

Inés Díaz Dorronsoro
Universidad de Navarra

Paloma Martín Moreno
Clínica Universidad de Navarra

Francisco Javier Lavilla
Clínica Universidad de Navarra

Armando Torres
Hospital Universitario de Canarias.

Universidad de La Laguna

Domingo Marrero Miranda
Hospital Universitario de Canarias

Aurelio Pastor Rodríguez Hernández
Hospital Universitario de Canarias

Eduardo De Bonis Redondo
Hospital Universitario de Canarias

Esteban Porrini
Universidad de La Laguna

María de los Ángeles Cobo Caso
Hospital Universitario de Canarias

María Lourdes Pérez Tamajón
Hospital Universitario de Canarias

Margarita Rufino Hernández
Hospital Universitario de Canarias

María Sagrario García Rebollo
Hospital Universitario de Canarias

Patricia Delgado Mallen
Hospital Universitario de Canarias

Alejandra Álvarez González
Hospital Universitario de Canarias

Ana María González Ríos
Hospital Universitario de Canarias

Rosa Miquel Rodríguez
Hospital Universitario de Canarias

Sara Estupiñan Torres
Hospital Universitario de Canarias

Diego Álvarez Sosa
Hospital Universitario de Canarias

Beatriz Escamilla Cabrera
Hospital Universitario de Canarias

Nayara Zamora Rodríguez
Hospital Universitario de Canarias

Armanda Farina Hernández
Hospital Universitario de Canarias

María José Rodríguez Gamboa
Hospital Universitario de Canarias

Cobo Caso, María de los Angeles
Hospital Universitario de Canarias

Perez Tamajón, María
Hospital Universitario de Canarias

Rufino Hernández, Margarita
Hospital Universitario de Canarias

García Rebollo, María Sagrario
Hospital Universitario de Canarias

Delgado Mallen, Patricia
Hospital Universitario de Canarias

Álvarez González, Alejandra
Hospital Universitario de Canarias

Gonzalez Ríos, Ana María
Hospital Universitario de Canarias

Miquel Rodríguez, Rosa
Hospital Universitario de Canarias

Estupiñan Torres, Sara
Hospital Universitario de Canarias

Álvarez Sosa, Diego
Hospital Universitario de Canarias

Escamilla Cabrera, Beatriz
Hospital Universitario de Canarias

Zamora Rodríguez, Nayara
Hospital Universitario de Canarias

Fariña Hernández, Armanda
Hospital Universitario de Canarias

Rodríguez Gamboa, María Jose
Hospital Universitario de Canarias

María Laura García Bermejo
Instituto Ramón y Cajal

Cobo Caso, María
Hospital Universitario de Canarias

Estefanya García-Meneñez
Fundación Investigación Biomédica Hospital Puerta de Hierro

Beatriz Sánchez-Sobrino
Fundación Investigación Biomédica Hospital Puerta de Hierro

Estefanya García-Meneñez
Fundación Investigación Biomédica Hospital Puerta de Hierro

Alberto Lázaro Fernández
Universidad Complutense de Madrid
REFERENCES

1. Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150

2. Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E et al. Clarifying the concept of chronic kidney disease for non-nephrologists. Clin Kidney J 2019; 12: 258–226

3. Matsushita K, Coresh J, Sang Y et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3: 514–525

4. Hallan SJ, Matsushita K, Sang Y et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308: 2349–2360

5. Ortiz A, Covic A, Fleris D et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383: 1831–1843

6. Chawla LS, Eggers PW, Star RA et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014; 371: 58–66

7. Martin-Cleary C, Molinero-Casares LM, Ortiz A et al. Development and internal validation of a prediction model for hospital-acquired acute kidney injury. Clin Kidney J 2021; 14: 309–316

8. ERA-EDTA Council, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant 2021; 36: 87–94

9. Williamson EJ, Walker AJ, Bhaskaran K et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430–436

10. Clark A, Jit M, Warren-Gash C et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health 2020; 8: e1003–e1017

11. Sanchez-Nino MD, Sanz AB, Ramos AM et al. Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase. Clin Kidney J 2017; 10: 188–191

12. Tofte N, Lindhardt M, Adamova K et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol 2020; 8: 301–312

13. Rodriguez-Ortiz ME, Pontillo C, Rodriguez M et al. Novel urinary biomarkers for improved prediction of progressive eGFR loss in early chronic kidney disease stages and in high risk individuals without chronic kidney disease. Sci Rep 2018; 8: 15940

14. Foreman KJ, Marquez N, Dolgert A et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018; 392: 2052–2090

15. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2018. Amsterdam: Amsterdam UMC, location AMC, Department of Medical Informatics, 2020. https://www.era-edta.org/registry/AnnRep2018.pdf (1 May 2021, date last accessed)

16. Kramer A, Boenink R, Noordzij M et al. The ERA-EDTA Registry Annual Report 2017: a summary. Clin Kidney J 2020; 13: 693–709

17. Vanholder R, Annemans L, Bello AK et al. Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. Clin Kidney J 2021; 14: 1719–1730

18. Organización Nacional de Trasplantes. Registro Espanol de Enfermos Renales. http://www.ont.es/infesp/Paginas/RegistroEnfermosRenales.aspx (1 May 2021, date last accessed)

19. Torra R, Furlano M, Ortiz A et al. Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports. Clin Kidney J 2021; 14: 1879–1885

20. Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med 2019; 380: 142–151

21. Connaughton DM, Bukhari S, Conlon P et al. The Irish kidney gene project–prevalence of family history in patients with kidney disease in Ireland. Nephron 2015; 130: 293–301

22. Mann JF, Hilgers KF. Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis. https://www.uptodate.com/contents/clinical-features-diagnosis-and-treatment-of-hypertensive-nephrosclerosis?_escaped_fragment_= (9 July 2020, date last accessed)

23. Carriazo S, Vanessa Perez-Gomez M, Ortiz A. Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology. Clin Kidney J 2020; 13: 504–509

24. Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008; 19: 2047–2051

25. Friedman DJ. COVID-19 and APOL1: understanding disease mechanisms through clinical observation. J Am Soc Nephrol 2021; 32: 1–2
26. Jager KJ, Kovesdy C, Langham R et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. *Kidney Int* 2019; 96: 1048–1050
27. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020; 395: 709–733
28. Soriano JB, Rojas-Rueda D, Alonso J et al. The burden of disease in Spain: results from the Global Burden of Disease 2016. *Med Clin (Barc)* 2018; 151: 171–190
29. Ortiz A, Sanchez-Niño MD, Crespo-Barrio M et al. The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem. *Nefrologia* 2019; 39: 29–34
30. Vollset SE, Goren E, Yuan CW et al. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. *Lancet* 2020; 396: 1285–1306
31. United Nations. Department of Economic and Social Affairs. Population dynamics. https://population.un.org/wpp/Graphs/DemographicProfiles/Pyramid/724 (1 May 2021, date last accessed)
32. Gorostidi M, Sánchez-Martínez M, Ruilope LM et al. Chronic kidney disease in Spain: prevalence and impact of accumulation of cardiovascular risk factors. *Nefrologia* 2018; 38: 606–615
33. Martín-Cleary C, Ortiz A. CKD hotspots around the world: where, why and what the lessons are. *A CKJ review series. Clin Kidney J* 2014; 7: 519–523
34. Murray R, Zimmerman T, Agarwal A et al. Kidney-related research in the United States: a position statement from the National Kidney Foundation and the American Society of Nephrology. *Am J Kidney Dis* 2021; 78: 161–167
35. https://www.isciii.es/QueHacemos/Financiacion/Documents/RD21/FAQs_RD_2021.pdf (1 March 2021, date last accessed)
36. Sanz AB, Sanchez-Niño MD, Ramos AM et al. NF-kappaB in renal inflammation. *J Am Soc Nephrol* 2010; 21: 1254–1262
37. Fernandez-Fernandez B, Izquierdo MC, Valiño-Rivas L et al. Albumin downregulates Klotho in tubular cells. *Nephrol Dial Transplant* 2018; 33: 1712–1722
38. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. *J Am Soc Nephrol* 2011; 22: 124–136
39. Moreno JA, Izquierdo MC, Sanchez-Niño MD et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. *J Am Soc Nephrol* 2011; 22: 1315–1325
40. Sanchis P, Ho CY, Liu Y et al. Arterial "inflammaging" drives vascular calcification in children on dialysis. *Kidney Int* 2019; 95: 958–972
41. Kooman JP, Kotanko P, Schols AM et al. Chronic kidney disease and premature ageing. *Nat Rev Nephrol* 2014; 10: 732–742
42. Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. *Kidney Int* 2014; 85: 1303–1309
43. European Kidney Health Alliance. Resolve the unmet needs of kidney patients in “The Decade of the Kidney”. http:// ekha.eu/wp-content/uploads/200910_EKHA_position_EU_new_farma_strategy.pdf (1 May 2021, date last accessed)
44. Fowler KJ. Advancing American Kidney Health (AAKH): catalyst for investment in kidney diseases clinical trials and precision medicine: an opportunity to advance upstream interventions and the importance of nephrology. *Clin J Am Soc Nephrol* 2020; 15: 1689–1691
45. Fernandez-Fernandez B, Mahillo I, Sanchez-Rodriguez J et al. Gender, albuminuria and chronic kidney disease progression in treated diabetic kidney disease. *J Clin Med* 2020; 9: 161
46. European Kidney Health Alliance. The Decade of the Kidney™. http://ekha.eu/the-decade-of-the-kidney/ (1 June 2021, date last accessed)